Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Quantum Biopharma ( (TSE:QNTM) ).
On July 31, 2025, Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., has launched a Regulation D 506(c) offering to raise up to $5 million for growth and a potential IPO. This capital raise will not dilute Quantum BioPharma shareholders, as the company maintains a 25% ownership in Unbuzzd until it reaches a $1 billion valuation. Unbuzzd’s offering is supported by partnerships with MZ Digital and Dealmaker, and allows investments through traditional and cryptocurrency payments. The funds will support Unbuzzd’s expansion plans and position it for a future IPO, potentially benefiting Quantum BioPharma through non-dilutive capital access and royalty payments.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in the research and development of its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation in multiple sclerosis. Quantum BioPharma also retains a significant stake in Unbuzzd Wellness Inc., which offers a beverage that accelerates alcohol metabolism and reduces hangover symptoms.
Average Trading Volume: 7,412
Technical Sentiment Signal: Buy
Current Market Cap: C$90.13M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.